Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephan Stilgenbauer

Showing results (291-300 of 466) with videos related to

Pageof 47
Sort By:
Blood|October 18, 2021
Evaluation of vecabrutinib as a model for noncovalent BTK/ITK inhibition for treatment of chronic lymphocytic leukemiaBilly Michael Chelliah Jebaraj, Annika Müller, Rashmi Priyadharshini Dheenadayalan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 31, 2016
Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study GroupGabor Kovacs, Sandra Robrecht, Anna Maria Fink, et al.
The Lancet. Oncology|October 5, 2019
Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort studyCarmen D Herling, Kevin R Coombes, Axel Benner, et al.
Blood|May 13, 2010
Deregulation of the telomerase reverse transcriptase (TERT) gene by chromosomal translocations in B-cell malignanciesInga Nagel, Monika Szczepanowski, José I Martín-Subero, et al.
Cancer Discovery|December 21, 2013
Evolution of DNA methylation is linked to genetic aberrations in chronic lymphocytic leukemiaChristopher C Oakes, Rainer Claus, Lei Gu, et al.
Blood Advances|June 9, 2026
PLCG2 Exon-Skipped Variants: Insights into Their Potential Role in Chronic Lymphocytic LeukemiaJialei Qi, Wen Li, Rashmi Priyadharshini Dheenadayalan, et al.
Blood|April 24, 2019
IGF1R as druggable target mediating PI3K-δ inhibitor resistance in a murine model of chronic lymphocytic leukemiaAnnika Scheffold, Billy Michael Chelliah Jebaraj, Eugen Tausch, et al.
Science Translational Medicine|January 17, 2020
Stromal cell protein kinase C-β inhibition enhances chemosensitivity in B cell malignancies and overcomes drug resistanceEugene Park, Jingyu Chen, Andrew Moore, et al.
Blood|May 27, 2016
Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapyCarmen Diana Herling, Marion Klaumünzer, Cristiano Krings Rocha, et al.
Science Immunology|July 30, 2017
Tumor-derived exosomes modulate PD-L1 expression in monocytesFranziska Haderk, Ralph Schulz, Murat Iskar, et al.
Pageof 47

Showing results (291-300 of 466) with videos related to

Sort By:
Pageof 47
Blood|October 18, 2021
Evaluation of vecabrutinib as a model for noncovalent BTK/ITK inhibition for treatment of chronic lymphocytic leukemiaBilly Michael Chelliah Jebaraj, Annika Müller, Rashmi Priyadharshini Dheenadayalan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 31, 2016
Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study GroupGabor Kovacs, Sandra Robrecht, Anna Maria Fink, et al.
The Lancet. Oncology|October 5, 2019
Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort studyCarmen D Herling, Kevin R Coombes, Axel Benner, et al.
Blood|May 13, 2010
Deregulation of the telomerase reverse transcriptase (TERT) gene by chromosomal translocations in B-cell malignanciesInga Nagel, Monika Szczepanowski, José I Martín-Subero, et al.
Cancer Discovery|December 21, 2013
Evolution of DNA methylation is linked to genetic aberrations in chronic lymphocytic leukemiaChristopher C Oakes, Rainer Claus, Lei Gu, et al.
Blood Advances|June 9, 2026
PLCG2 Exon-Skipped Variants: Insights into Their Potential Role in Chronic Lymphocytic LeukemiaJialei Qi, Wen Li, Rashmi Priyadharshini Dheenadayalan, et al.
Blood|April 24, 2019
IGF1R as druggable target mediating PI3K-δ inhibitor resistance in a murine model of chronic lymphocytic leukemiaAnnika Scheffold, Billy Michael Chelliah Jebaraj, Eugen Tausch, et al.
Science Translational Medicine|January 17, 2020
Stromal cell protein kinase C-β inhibition enhances chemosensitivity in B cell malignancies and overcomes drug resistanceEugene Park, Jingyu Chen, Andrew Moore, et al.
Blood|May 27, 2016
Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapyCarmen Diana Herling, Marion Klaumünzer, Cristiano Krings Rocha, et al.
Science Immunology|July 30, 2017
Tumor-derived exosomes modulate PD-L1 expression in monocytesFranziska Haderk, Ralph Schulz, Murat Iskar, et al.
Pageof 47